Titre du document / Document title
Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Commentary
Auteur(s) / Author(s)
ETTINGER B. ;
PAK C. Y. C. ;
CITRON J. T. ;
THOMAS C. ;
ADAMS-HUET B. ;
VANGESSEL A. ;
PREMINGER G. M. (Commentateur)
(1) ;
Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)
(1) Division of Urology, Duke University Medical Center, Durham, North Carolina, ETATS-UNIS
Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, ETATS-UNIS
Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, ETATS-UNIS
Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, ETATS-UNIS
Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, ETATS-UNIS
Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California, ETATS-UNIS
Résumé / Abstract
Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6% of subjects receiving placebo and in 12.9% of subjects receiving potassium-magnesium citrate. When compared with placebo, the relative risk of treatment failure for potassium-magnesium citrate was 0.16 (95% confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10, 95% confidence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities. Conclusions: Potassium-magnesium citrate effectively prevents recurrent calcium oxalate stones, and this treatment given for up to 3 years reduces risk of recurrence by 85%.
Revue / Journal Title
The Journal of urology
ISSN
0022-5347
CODEN JOURAA
Source / Source
1997, vol. 158, n
o6, pp. 2069-2073 (14 ref.)
Langue / Language
Anglais
Editeur / Publisher
Elsevier, New York, NY, ETATS-UNIS
(1917)
(Revue)
Mots-clés anglais / English Keywords
;
;
;
;
;
;
;
;
;
;
;
;
;
;
Mots-clés français / French Keywords
;
;
;
;
;
;
;
;
;
;
;
;
;
;
Mots-clés espagnols / Spanish Keywords
;
;
;
;
;
;
;
;
;
;
;
;
;
;
Localisation / Location
INIST-CNRS, Cote INIST : 2081, 35400007936884.0070
Nº notice refdoc (ud4) : 2068785
